Sting of Alzheimer's failures offset by upcoming prevention trials

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature reviews. Drug discovery

• Publication date

  2012-08-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrd3842PMID 22935790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Network mechanism analysis between hippocampal development and Alzheimer's disease

  2025cites this paper
• Mitochondrial bioenergetics stimulates autophagy for pathological MAPT/Tau clearance in tauopathy neurons

  2024cites this paper
• Review of Pharmacotherapeutic Targets in Alzheimer’s Disease and Its Management Using Traditional Medicinal Plants

  2024cites this paper
• A Brief Review of Alzheimer’s Disease

  2021cites this paper
• Aging, Dementia, and Alzheimer Disease

  2021cites this paper
• Shared Mechanisms of Disease

  2021cites this paper
• Structural biology of cell surface receptors implicated in Alzheimer’s disease

  2021cites this paper
• Exploring the Multi–Target Neuroprotective Chemical Space of Benzofuran Scaffolds: A New Strategy in Drug Development for Alzheimer’s Disease

  2020cites this paper
• Hydroxytyrosol Acetate Improves the Cognitive Function of APP/PS1 Transgenic Mice in ERβ-dependent Manner.

  2020cites this paper
• Human serum albumin-mediated recognition of soluble amyloid-β peptides using a time-resolved luminescent probe in plasma.

  2020cites this paper
• Role of Withaferin A as a Neuroprotectant against Beta Amyloid Induced Toxicity and associated mechanism

  2019cites this paper
• Biomarkers voor de ziekte van Alzheimer: relaties met vasculaire factoren, neurodegeneratie en cognitie in de predementiële fasen

  2019cites this paper
• Age at onset in genetic prion disease and the design of preventive clinical trials.

  2019cites this paper
• Pharmacological BACE1 inhibitor treatment during early progression of β-amyloid pathology maximizes therapeutic efficacy

  2018cites this paper
• Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease.

  2018cites this paper
• Age of onset in genetic prion disease and the design of preventive clinical trials

  2018cites this paper
• Design and synthesis of multipotent 3-aminomethylindoles and 7-azaindoles with enhanced protein phosphatase 2A-activating profile and neuroprotection.

  2018cites this paper
• Iron and Alzheimer’s Disease: From Pathogenesis to Therapeutic Implications

  2018cites this paper
• Subthreshold Amyloid Predicts Tau Deposition in Aging

  2018cites this paper
• Nutrition for the ageing brain: Towards evidence for an optimal diet.

  2017cites this paper
• Resveratrol for Alzheimer's disease

  2017cites this paper
• Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.

  2017cites this paper
• Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target

  2017cites this paper
• The Transcription Factor XBP1 in Memory and Cognition: implications in Alzheimer’s Disease

  2017cites this paper
• The Transcription Factor XBP 1 in Memory and Cognition : implications in Alzheimer ’ s Disease

  2017cites this paper
• Gramine Derivatives Targeting Ca(2+) Channels and Ser/Thr Phosphatases: A New Dual Strategy for the Treatment of Neurodegenerative Diseases.

  2016cites this paper
• Alzheimer's disease: The amyloid hypothesis on trial

  2016cites this paper
• Sex differences in metabolic aging of the brain: insights into female susceptibility to Alzheimer's disease.

  2016cites this paper
• utrition for the ageing brain: Towards evidence for an optimal diet

  2016cites this paper
• Human ApoE ɛ2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H+-ATPase

  2016cites this paper
• Medicinal Chemistry Focusing on Aggregation of Amyloid-β.

  2016cites this paper
• Developing an Alzheimer’s Disease Therapeutic: Identification and Validation of Signaling Pathways Involved in Small Molecule Induction of Nerve Growth Factor

  2016cites this paper
• Structure-Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimer's Disease Brains.

  2015cites this paper
• Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

  2015cites this paper
• Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer’s Disease Prevention and Early Intervention

  2015cites this paper
• Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies.

  2015cites this paper
• Statistically quantified measurement of an Alzheimer's marker by surface‐enhanced Raman scattering

  2015cites this paper
• Synthetic Routes for Phenylethenyl and ( 3-Pyridinyl ) ethenyl Benzothiazole Derivatives ( A ) and Their Precursors ( B ) Scheme 2 . Synthetic Routes for Phenylethenyl ( A ) and ( 3-Pyridinyl ) ethenyl ( B ) Benzoxazole Derivatives

  2015cites this paper
• Blood-brain barrier-permeable fluorone-labeled dieckols acting as neuronal ER stress signaling inhibitors.

  2015cites this paper
• Towards universal therapeutics for memory disorders.

  2015cites this paper
• Parkinson’s disease: From human genetics to clinical trials

  2015cites this paper
• S-Nitrosylation in Alzheimer's disease

  2015cites this paper
• Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics.

  2015cites this paper
• Biomarkers in Sporadic and Familial Alzheimer’s Disease

  2015cites this paper
• Disclosure of research results in genetic studies of Parkinson's disease caused by LRRK2 mutations

  2015cites this paper
• Targeting microglia for the treatment of Alzheimer’s disease

  2015cites this paper
• Cognition, Brain Atrophy, and Cerebrospinal Fluid Biomarkers Changes from Preclinical to Dementia Stage of Alzheimer's Disease and the Influence of Apolipoprotein E

  2015cites this paper
• Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches

  2014cites this paper
• Design, synthesis and biological evaluation of novel tricyclics as dual cholinesterase (ChE) and amyloid aggregation inhibitors with antioxidant properties

  2014cites this paper
• [Mild neurocognitive disorder - a disease? Against].

  2014cites this paper
• Laser nanostructuring for surface enhanced sensing: methods and applications

  2014cites this paper
• Lipid Regulation as a Critical Factor in the Development of Alzheimer's Disease

  2014cites this paper
• Synthese und Evaluation neuer Inhibitoren und Modulatoren von Proteasen und Kinasen in Modellen der Alzheimer-Demenz und akuter myeloischer Leukämie

  2014cites this paper
• Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity

  2014cites this paper
• Frontiers in therapeutic development of allopregnanolone for Alzheimer’s disease and other neurological disorders

  2014cites this paper
• Neuronal Cellular Responses to Extremely Low Frequency Electromagnetic Field Exposure: Implications Regarding Oxidative Stress and Neurodegeneration

  2014cites this paper
• Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels

  2014cites this paper
• Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB

  2014cites this paper
• Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis.

  2014cites this paper
• Failure analysis of clinical trials to test the amyloid hypothesis

  2014cites this paper
• Altered Proteolysis in Fibroblasts of Alzheimer Patients with Predictive Implications for Subjects at Risk of Disease

  2014cites this paper
• Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β

  2014cites this paper
• Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease

  2014cites this paper
• „Mild neurocognitive disorder“ – eine Erkrankung? Kontra

  2014cites this paper
• The role of human cognitive neuroscience in drug discovery for the dementias.

  2014cites this paper
• Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target?

  2014cites this paper
• Dementia 2014: Opportunity for Change

  2014cites this paper
• A new regulatory road-map for Alzheimer's disease drug development.

  2014cites this paper
• Adapting to Dementia in Society: A Challenge for Our Lifetimes and a Charge for Public Health

  2014cites this paper
• Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models.

  2014cites this paper
• On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis.

  2014cites this paper
• Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.

  2014cites this paper
• Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: Conceptual framework and example

  2014cites this paper
• Insulin growth factor binding protein 7 is a novel target to treat dementia.

  2014cites this paper
• Plaques and tangles: birthmarks of the aging soul. Preface.

  2014cites this paper
• Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers.

  2014cites this paper
• Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise.

  2014cites this paper
• Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement

  2013cites this paper
• A new face for old antibiotics: tetracyclines in treatment of amyloidoses.

  2013cites this paper
• Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls

  2013cites this paper
• BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases

  2013cites this paper
• Development and mechanism of γ-secretase modulators for Alzheimer's disease.

  2013cites this paper
• Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer’s disease

  2013cites this paper
• A new roadmap for drug development for Alzheimer's disease

  2013cites this paper
• Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease

  2013cites this paper
• J-147 a Novel Hydrazide Lead Compound to Treat Neurodegeneration: CeeTox™ Safety and Genotoxicity Analysis

  2013cites this paper
• A Semi‐Physiological Model of Amyloid‐β Biosynthesis and Clearance in Human Cerebrospinal Fluid: A Tool for Alzheimer's Disease Research and Drug Development

  2013cites this paper
• Alzheimer's disease risk genes and the age-at-onset phenotype.

  2013cites this paper
• Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.

  2013cites this paper
• Metal Dyshomeostasis and Inflammation in Alzheimer's and Parkinson's Diseases: Possible Impact of Environmental Exposures

  2013influential citation
• Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation

  2013cites this paper
• Reversal Learning and Associative Memory Impairments in a BACHD Rat Model for Huntington Disease

  2013cites this paper
• Prion-Like Propagation of Protein Aggregation and Related Therapeutic Strategies

  2013cites this paper
• Non-pharmacological interventions and neuroplasticity in early stage Alzheimer's disease

  2013cites this paper
• The Women's Healthy Ageing Project: Fertile ground for investigation of healthy participants ‘at risk’ for dementia

  2013cites this paper
• The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy

  2013cites this paper
• Cellular Prion Protein as a Therapeutic Target in Alzheimer's Disease

  2013cites this paper
• The Journey From Metabolic Profiling to Biomarkers: The Potential of NMR Spectroscopy Based Metabolomics in Neurodegenerative Disease Research

  2013cites this paper
• Synapses, spines, zinc and pathology of Alzheimer's disease.

  2013cites this paper
• Synaptic function as a preclinical and experimental medicine readout for disease-modifying therapy in Alzheimer's Disease

  2013cites this paper